Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy | SpringerLink
Adjuvant systemic therapy for HER2-positive breast cancer - UpToDate
SWOG S 0800 ( NCI CDR 0000636131 ) : addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response ( pCR ) rates in inflammatory or locally
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive Review
Chemotherapy Protocol
Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Chemotherapy for Uterus Cancer
Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052) | Scientific Reports
PDF) Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer
Pregnancy-Associated Breast Cancer
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer -
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
4102-Breast adjuvant/neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense | eviQ
Frontiers | Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content | JCO Clinical Cancer Informatics
Adjuvant systemic therapy for HER2-positive breast cancer - UpToDate
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet
National Surgical Adjuvant Breast and Bowel Project (NSABP)
